Cargando…

742. Breakthrough Invasive Fungal Infections with Isavuconazonium Sulfate versus Voriconazole as Primary Antifungal Prophylaxis in Patients with Acute Myeloid Leukemia (AML) who Received Induction Chemotherapy

BACKGROUND: Fungal infections in patients with hematologic malignancies are associated with high mortality. Primary antifungal prophylaxis has been shown to be a more effective strategy than treating a documented infection. This retrospective analysis aims to compare the rates of breakthrough invasi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singam, Hareesh v, Pasikhova, Yanina, Quilitz, Rod, Greene, John N, Baluch, Aliyah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777809/ http://dx.doi.org/10.1093/ofid/ofaa439.932

Ejemplares similares

1301. Breakthrough Invasive Fungal Infections based on CYP2C19 Levels in Patients Who were on Voriconazole as Primary Antifungal Prophylaxis in Acute Myeloid Leukemia (AML) undergoing Induction Chemotherapy
por: Singam, Hareesh v, et al.
Publicado: (2020)

483. Use of Terbinafine in Combination with Other Systemic Anti-fungal Agents As Treatment for Invasive Mold Infections. Experience from A National Cancer Institute Designated Cancer Center.
por: Ajayi, Eloho, et al.
Publicado: (2022)

755. Clostridioides difficile Testing and the Use of Laxatives in Immunocompromised Adults
por: Al-Bahou, Amanda, et al.
Publicado: (2021)

Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center
por: Van Matre, Edward T., et al.
Publicado: (2019)

Early Antimicrobial De-escalation and Stewardship in Adult Hematopoietic Stem Cell Transplantation Recipients: Retrospective Review
por: Snyder, Matthew, et al.
Publicado: (2017)

Evaluating Initial Empiric Therapy for Neutropenic Fever in Vancomycin-Resistant Enterococcus-Colonized Patients
por: Snyder, Matthew, et al.
Publicado: (2021)

Evaluation of Amebicidal and Cysticidal Activities of Antifungal Drug Isavuconazonium Sulfate against Acanthamoeba T4 Strains
por: Shing, Brian, et al.
Publicado: (2021)

Intestinal Coccidian Infections in Cancer Patients: A Case Series
por: Einhorn, Nathan, et al.
Publicado: (2023)

The Role of Isavuconazonium Sulphate for the Treatment of Blastomycosis: A Case Series and Antifungal Susceptibility
por: Scolarici, Michael J, et al.
Publicado: (2022)

Safety, Tolerability, and Population Pharmacokinetics of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients
por: Arrieta, Antonio C., et al.
Publicado: (2021)

Disseminated Toxoplasmosis in an Allogeneic Hematopoietic Stem Cell Transplant Recipient: A Case Report and Review of the Current Literature
por: Baluch, Aliyah, et al.
Publicado: (2022)

1585. Isavuconazonium Sulfate plus Micafungin Improves Survival in an Immunocompromised Murine Model of Disseminated Fusariosis
por: Mavridou, Eleftheria, et al.
Publicado: (2019)

Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Isavuconazonium Sulfate in Healthy Adult Japanese Subjects
por: Shirae, Shinichiro, et al.
Publicado: (2022)

1699. Safety and Outcomes of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis or Invasive Mucormycosis in Pediatric Patients
por: Arrieta, Antonio C, et al.
Publicado: (2023)

Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation
por: Marks, David I, et al.
Publicado: (2011)

Comparative study of posaconazole and voriconazole for primary antifungal prophylaxis in patients with pediatric acute leukemia
por: Tu, Songji, et al.
Publicado: (2023)

Immunogenicity of the COVID-19 Two-Vaccination Series Among Hematologic Malignancies: Report of Three Cases of Breakthrough Infection
por: Pasikhova, Yanina, et al.
Publicado: (2022)

Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats
por: Schmitt-Hoffmann, Anne-Hortense, et al.
Publicado: (2017)

742 Evaluation of Anti-Xa Levels and Venous Thromboembolism Prophylaxis with Enoxaparin in Burn Patients
por: Boyd, Allison, et al.
Publicado: (2023)

755. Posaconazole versus voriconazole as antifungal prophylaxis for invasive fungal diseases in patients with hematological malignancies
por: Almutairy, Reem F, et al.
Publicado: (2020)

1023. Isavuconazonium Use at an Academic Transplant Center
por: Servais, Abigail, et al.
Publicado: (2019)

1320. Pharmacokinetics of Isavuconazole Administered as Isavuconazonium Sulfate Intravenous Solution via Nasogastric Tube or Orally in Healthy Volunteers
por: Desai, Amit, et al.
Publicado: (2020)

Pharmacokinetics and Bioequivalence of Isavuconazole Administered as Isavuconazonium Sulfate Intravenous Solution via Nasogastric Tube or Orally in Healthy Subjects
por: Desai, Amit, et al.
Publicado: (2021)

A Pharmacokinetic Bioequivalence Study Comparing Different‐Strength and ‐Size Capsules of Isavuconazonium Sulfate in Healthy Japanese Subjects
por: Shirae, Shinichiro, et al.
Publicado: (2022)

SAT-742 Characterising the Metabolism, Glucuronidation and Sulfation of C11-oxy C(19) Steroids
por: Toit, Therina Du, et al.
Publicado: (2020)

1291. Safety of Isavuconazole Compared with Voriconazole as Primary Antifungal Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients
por: Bogler, Yael, et al.
Publicado: (2020)

Breakthrough Invasive Fungal Infection After Coadministration of Venetoclax and Voriconazole
por: Hall, Victoria G, et al.
Publicado: (2023)

1396. Predictions of Isavuconazonium Sulfate Dosage in Patients Aged 6 Months: <18 Years by Physiologically Based Pharmacokinetic Modeling
por: Desai, Amit, et al.
Publicado: (2018)

Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation
por: Döring, M., et al.
Publicado: (2013)

Scaling of mortality in 742 metropolitan areas of the Americas
por: Bilal, Usama, et al.
Publicado: (2021)

1129. Targeted Voriconazole Prophylaxis in Heart Transplantation Recipients
por: Lin, Michael, et al.
Publicado: (2018)

Isavuconazonium for the treatment of Purpureocillium lilacinum infection in a patient with pyoderma gangrenosum
por: Accetta, Julia, et al.
Publicado: (2020)

2122. Isavuconazonium for Invasive Fungal Therapy: Single-Center Pediatric Experience
por: Mongkolrattanothai, Kanokporn, et al.
Publicado: (2019)

Isavuconazonium/pneumococcal vaccine: Vaccine failure and other toxicities: case report
Publicado: (2022)

971. Breakthrough Invasive Fungal Infections (IFI) in Acute Leukemia (AL) Patients Receiving Antifungal Prophylaxis
por: Wasylyshyn, Anastasia, et al.
Publicado: (2018)

974. Real World Experience of Posaconazole Therapeutic Drug Monitoring in Oncology Patients: Clinical Implications of Hypoalbuminemia as a Predictor of Subtherapeutic Posaconazole Levels
por: Pasikhova, Yanina, et al.
Publicado: (2023)

Two Phase 1, Open‐Label, Mass Balance Studies to Determine the Pharmacokinetics of (14)C‐Labeled Isavuconazonium Sulfate in Healthy Male Volunteers
por: Townsend, Robert, et al.
Publicado: (2017)

CCNP Wireless (642-742 IUWVN) quick reference
por: Henry, Jerome
Publicado: (2012)

2112. Voriconazole for Primary Prophylaxis: A Decade of Trends and Outcomes
por: Mourad, Ahmad, et al.
Publicado: (2019)

Antifungal Prophylaxis
por: Johnson, Douglas Clark, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pk1k7ms2eh5ovfe2f4itdtq6a6